| Accession |
PRJCA013230 |
| Title |
CheckMate 227, CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 227 |
| Relevance |
Medical |
| Data types |
biomaker PD-L1/EGFR/PK/IMG data
|
| Organisms |
Homo sapiens
|
| Description |
This study is a randomized, open-label Phase 3 trial of nivolumab monotherapy or nivolumab plus ipilimumabor nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy alone in subjects with chemotherapy naive stage IV or recurrent NSCLC. The central questions of the study will be to determine if: Part 2: nivolumab plus platinum doublet chemotherapy (Arm H), improves OS compared with platinum doublet chemotherapy (Arm I) in subjects with stage IV or recurrent NSCLC, regardless of PD-L1 expression level. |
| Sample scope |
Multiisolate |
| Release date |
2022-11-15 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Bristol-Myers Squibb (China) Investment Co., Ltd., Bristol-Myers Squibb Company
|
|
2016L10761/759/2017B02543/02681
|
|
|
|
| Submitter |
Xiaoxiao
Wang (mandy.wang@bms.com)
|
| Organization |
Bristol-Myers Squibb (China) Investment Co., Ltd. |
| Submission date |
2022-11-15 |
